Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...
There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.
The European Commission has followed the advice of its human medicines committee and revoked the conditional marketing authorisation for Advanz Pharma's Ocaliva therapy for primary biliary ...
The European Commission revoked the conditional marketing authorisation for Ocaliva (obeticholic acid) earlier this year on the grounds that its benefits no longer outweighed its risks as a ...
Hosted on MSN20d
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 DrugInflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing authorization, under exceptional circumstances, for Gohibic (vilobelimab ...
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...
From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...
The multinational biopharma company, which has operations on Cambridge Science Park, reveals that its solution tarlatamab (IMDYLLTRA®), has been granted a conditional marketing authorisation by the UK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback